Please enable JavaScript to continue using this application.

Compare $GNLX vs $VTVT | Chartloom

Compare

$GNLX vs $VTVT

Genelux Corp · vTv Therapeutics Inc

GNLX

Genelux Corp

VTVT

vTv Therapeutics Inc

Compare $GNLX vs $VTVT

Comparing Genelux Corp and vTv Therapeutics Inc

GNLXGenelux Corp

VTVTvTv Therapeutics Inc

GNLXGenelux Corp

Market cap

$115M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-43.7%

52W performance

-46.1%

FCF yield

-25.0%

VTVTvTv Therapeutics Inc

Market cap

$123M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

216600.0%

YTD performance

-21.3%

52W performance

38.3%

FCF yield

-13.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GNLX

VTVT

Detailed metrics comparison

GNLX

Genelux Corp

VTVT

vTv Therapeutics Inc

Market Cap

GNLX$115M

VTVT$123M

Enterprise Value

GNLX$106M

VTVT$36M

Price

GNLX$2.56

VTVT$31.18

P/E Ratio

GNLXN/A

VTVTN/A

P/S Ratio

GNLX14,348.80x

VTVT3.33x

EV/Sales

GNLX13,200.80x

VTVT0.98x

EV/EBITDA

GNLX0.00x

VTVT0.00x

P/B Ratio

GNLX7.19x

VTVT1.53x

P/FCF Ratio

GNLXN/A

VTVTN/A

EV/FCF

GNLX-3.68x

VTVT-2.16x

PEG Ratio

GNLXN/A

VTVTN/A

Forward P/E (NTM)

GNLXN/A

VTVTN/A

Forward P/S (NTM)

GNLXN/A

VTVTN/A

Revenue (TTM)

GNLX$8K

VTVT$37M

Revenue Growth (YoY)

GNLXN/A

VTVT216600.0%

Forward Rev Growth

GNLX551.6%

VTVT-97.3%

Gross Margin (TTM)

GNLX0.0%

VTVT0.0%

Operating Margin (TTM)

GNLX0.0%

VTVT63.1%

EBITDA Margin (TTM)

GNLX-453500.0%

VTVT-25.1%

Net Margin (TTM)

GNLX-444950.0%

VTVT-12.9%

FCF Margin (TTM)

GNLX-358537.5%

VTVT-45.5%

Net Income (TTM)

GNLX$-36M

VTVT$-5M

FCF (TTM)

GNLX$-29M

VTVT$-17M

EPS (TTM)

GNLX-$0.79

VTVT-$0.38

ROE (TTM)

GNLX-20585.0%

VTVT-627.0%

ROA (TTM)

GNLX-13879.0%

VTVT-506.0%

ROIC (TTM)

GNLX-20585.0%

VTVT-626.0%

Cash

GNLX$9M

VTVT$87M

Debt

GNLX$0

VTVT$0

Net Cash/Debt

GNLX$9M

VTVT$87M

Current Ratio (TTM)

GNLX2.39x

VTVT12.48x

Quick Ratio (TTM)

GNLX2.33x

VTVT12.42x

Debt/Equity (TTM)

GNLX0.00x

VTVT0.00x

Debt/Assets (TTM)

GNLX0.0%

VTVT0.0%

Interest Coverage (TTM)

GNLXN/A

VTVTN/A

Net Debt/EBITDA (TTM)

GNLX0.00x

VTVT0.00x

Beta

GNLX0.56

VTVT0.23

52W Performance

GNLX-46.1%

VTVT38.3%

YTD Performance

GNLX-43.7%

VTVT-21.3%

% from 52W High

GNLX-70.0%

VTVT-29.1%

% from 52W Low

GNLX11.8%

VTVT59.9%

Asset Turnover (TTM)

GNLX0.00x

VTVT0.37x

FCF Yield (TTM)

GNLX-25.0%

VTVT-13.6%

Earnings Yield (TTM)

GNLX-31.0%

VTVT-3.9%

Dividend Yield (TTM)

GNLXN/A

VTVTN/A

Rule of 40

GNLX-358,537.5

VTVT216,554.5

EV/GP/RG

GNLXN/A

VTVTN/A

Ticker research

View GNLX research View VTVT research

Metric	GNLX Genelux Corp	VTVT vTv Therapeutics Inc
Market & Valuation
Market Cap	$115M	$123M
Enterprise Value	$106M	$36M
Price	$2.56	$31.18
P/E Ratio	N/A	N/A
P/S Ratio	14,348.80x	3.33x
EV/Sales	13,200.80x	0.98x
EV/EBITDA	0.00x	0.00x
P/B Ratio	7.19x	1.53x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.68x	-2.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$8K	$37M
Revenue Growth (YoY)	N/A	216600.0%
Forward Rev Growth	551.6%	-97.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	63.1%
EBITDA Margin (TTM)	-453500.0%	-25.1%
Net Margin (TTM)	-444950.0%	-12.9%
FCF Margin (TTM)	-358537.5%	-45.5%
Net Income (TTM)	$-36M	$-5M
FCF (TTM)	$-29M	$-17M
EPS (TTM)	-$0.79	-$0.38
ROE (TTM)	-20585.0%	-627.0%
ROA (TTM)	-13879.0%	-506.0%
ROIC (TTM)	-20585.0%	-626.0%
Financial Health
Cash	$9M	$87M
Debt	$0	$0
Net Cash/Debt	$9M	$87M
Current Ratio (TTM)	2.39x	12.48x
Quick Ratio (TTM)	2.33x	12.42x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.56	0.23
52W Performance	-46.1%	38.3%
YTD Performance	-43.7%	-21.3%
% from 52W High	-70.0%	-29.1%
% from 52W Low	11.8%	59.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.37x
FCF Yield (TTM)	-25.0%	-13.6%
Earnings Yield (TTM)	-31.0%	-3.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-358,537.5	216,554.5
EV/GP/RG	N/A	N/A
Ticker research	View GNLX research	View VTVT research

Valuation

P/S Ratio

VTVT

3.33x

GNLX

14,348.80x

EV/FCF

GNLX

-3.68x

VTVT

-2.16x

Growth & revenue

Revenue Growth TTM

VTVT

216600.0%

Forward Revenue Growth

GNLX

551.6%

VTVT

-97.3%

Profitability & performance

Gross Margin

GNLX

0.0%

VTVT

0.0%

ROE

VTVT

-627.0%

GNLX

-20585.0%

FCF Yield %

VTVT

-13.6%

GNLX

-25.0%

52-Week Performance

VTVT

38.3%

GNLX

-46.1%

Detailed metrics comparison

GNLX

Genelux Corp

VTVT

vTv Therapeutics Inc

Market Cap

GNLX$115M

VTVT$123M

Enterprise Value

GNLX$106M

VTVT$36M

Price

GNLX$2.56

VTVT$31.18

P/E Ratio

GNLXN/A

VTVTN/A

P/S Ratio

GNLX14,348.80x

VTVT3.33x

EV/Sales

GNLX13,200.80x

VTVT0.98x

EV/EBITDA

GNLX0.00x

VTVT0.00x

P/B Ratio

GNLX7.19x

VTVT1.53x

P/FCF Ratio

GNLXN/A

VTVTN/A

EV/FCF

GNLX-3.68x

VTVT-2.16x

PEG Ratio

GNLXN/A

VTVTN/A

Forward P/E (NTM)

GNLXN/A

VTVTN/A

Forward P/S (NTM)

GNLXN/A

VTVTN/A

Revenue (TTM)

GNLX$8K

VTVT$37M

Revenue Growth (YoY)

GNLXN/A

VTVT216600.0%

Forward Rev Growth

GNLX551.6%

VTVT-97.3%

Gross Margin (TTM)

GNLX0.0%

VTVT0.0%

Operating Margin (TTM)

GNLX0.0%

VTVT63.1%

EBITDA Margin (TTM)

GNLX-453500.0%

VTVT-25.1%

Net Margin (TTM)

GNLX-444950.0%

VTVT-12.9%

FCF Margin (TTM)

GNLX-358537.5%

VTVT-45.5%

Net Income (TTM)

GNLX$-36M

VTVT$-5M

FCF (TTM)

GNLX$-29M

VTVT$-17M

EPS (TTM)

GNLX-$0.79

VTVT-$0.38

ROE (TTM)

GNLX-20585.0%

VTVT-627.0%

ROA (TTM)

GNLX-13879.0%

VTVT-506.0%

ROIC (TTM)

GNLX-20585.0%

VTVT-626.0%

Cash

GNLX$9M

VTVT$87M

Debt

GNLX$0

VTVT$0

Net Cash/Debt

GNLX$9M

VTVT$87M

Current Ratio (TTM)

GNLX2.39x

VTVT12.48x

Quick Ratio (TTM)

GNLX2.33x

VTVT12.42x

Debt/Equity (TTM)

GNLX0.00x

VTVT0.00x

Debt/Assets (TTM)

GNLX0.0%

VTVT0.0%

Interest Coverage (TTM)

GNLXN/A

VTVTN/A

Net Debt/EBITDA (TTM)

GNLX0.00x

VTVT0.00x

Beta

GNLX0.56

VTVT0.23

52W Performance

GNLX-46.1%

VTVT38.3%

YTD Performance

GNLX-43.7%

VTVT-21.3%

% from 52W High

GNLX-70.0%

VTVT-29.1%

% from 52W Low

GNLX11.8%

VTVT59.9%

Asset Turnover (TTM)

GNLX0.00x

VTVT0.37x

FCF Yield (TTM)

GNLX-25.0%

VTVT-13.6%

Earnings Yield (TTM)

GNLX-31.0%

VTVT-3.9%

Dividend Yield (TTM)

GNLXN/A

VTVTN/A

Rule of 40

GNLX-358,537.5

VTVT216,554.5

EV/GP/RG

GNLXN/A

VTVTN/A

Ticker research

View GNLX research View VTVT research

Metric	GNLX Genelux Corp	VTVT vTv Therapeutics Inc
Market & Valuation
Market Cap	$115M	$123M
Enterprise Value	$106M	$36M
Price	$2.56	$31.18
P/E Ratio	N/A	N/A
P/S Ratio	14,348.80x	3.33x
EV/Sales	13,200.80x	0.98x
EV/EBITDA	0.00x	0.00x
P/B Ratio	7.19x	1.53x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.68x	-2.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$8K	$37M
Revenue Growth (YoY)	N/A	216600.0%
Forward Rev Growth	551.6%	-97.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	63.1%
EBITDA Margin (TTM)	-453500.0%	-25.1%
Net Margin (TTM)	-444950.0%	-12.9%
FCF Margin (TTM)	-358537.5%	-45.5%
Net Income (TTM)	$-36M	$-5M
FCF (TTM)	$-29M	$-17M
EPS (TTM)	-$0.79	-$0.38
ROE (TTM)	-20585.0%	-627.0%
ROA (TTM)	-13879.0%	-506.0%
ROIC (TTM)	-20585.0%	-626.0%
Financial Health
Cash	$9M	$87M
Debt	$0	$0
Net Cash/Debt	$9M	$87M
Current Ratio (TTM)	2.39x	12.48x
Quick Ratio (TTM)	2.33x	12.42x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.56	0.23
52W Performance	-46.1%	38.3%
YTD Performance	-43.7%	-21.3%
% from 52W High	-70.0%	-29.1%
% from 52W Low	11.8%	59.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.37x
FCF Yield (TTM)	-25.0%	-13.6%
Earnings Yield (TTM)	-31.0%	-3.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-358,537.5	216,554.5
EV/GP/RG	N/A	N/A
Ticker research	View GNLX research	View VTVT research